Department of Gastroenterology and Hepatology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
J Gastroenterol. 2021 May;56(5):434-441. doi: 10.1007/s00535-021-01767-2. Epub 2021 Feb 11.
Second primary cancers have impact on survival in patients who achieved cure for the first esophageal cancer. We, therefore, assessed the risk of incidence and mortality for second primary cancer by calculating standardized incidence ratio (SIR) and standardized mortality ratio (SMR) in patients with superficial or localized esophageal cancer without lymph node metastases as the first cancer (index cancer).
Data on cancer development and subsequent causes of deaths were collected from integrated database of the Osaka Cancer Registry and the Vital Statistics of Japan. Records with information on patients with index esophageal cancer diagnosed between 2004 and 2013 were extracted from the database. Then, SIR and SMR for second primary cancers that developed in other organ were calculated with the reference to the general population during the same period. All probability values are two-tailed.
Of 473,784 case records, 3022 cases of patients with index esophageal cancer were identified. Significantly higher SMRs/SIRs for cancers in mouth/pharynx, larynx, pancreas, and leukemia were confirmed with the values of 10.78/16.16, 8.56/6.44, 2.33/2.31, and 3.96/4.42, respectively. Significantly, higher SIRs for stomach, lung, and skin cancers were confirmed with the values of 2.84, 2.36, and 3.38, respectively, while SMRs were not significantly higher in these cancers.
Significantly higher risks for mouth/pharynx, larynx, pancreas, and leukemia as second cancers were clarified. Careful surveillance for these cancers is required for esophageal cancer patients.
对于首次食管癌治愈的患者,第二原发癌会影响其生存。因此,我们通过计算无淋巴结转移的表浅或局限型食管癌患者(索引癌)的标准化发病比(SIR)和标准化死亡比(SMR),评估了第二原发癌的发病和死亡风险。
从日本大阪癌症登记处和人口动态统计数据库的综合数据库中收集癌症发展和随后死亡原因的数据。从数据库中提取了索引食管癌诊断时间在 2004 年至 2013 年之间的患者记录。然后,用同期的一般人群作为参照,计算发生于其他器官的第二原发癌的 SIR 和 SMR。所有概率值均为双尾。
在 473784 例病例记录中,确定了 3022 例索引食管癌患者。与一般人群相比,口腔/咽部、喉、胰腺和白血病的 SMR/SIR 显著更高,分别为 10.78/16.16、8.56/6.44、2.33/2.31 和 3.96/4.42。值得注意的是,胃癌、肺癌和皮肤癌的 SIR 显著更高,分别为 2.84、2.36 和 3.38,而这些癌症的 SMR 并没有显著升高。
明确了口腔/咽部、喉、胰腺和白血病发生第二原发癌的风险显著升高。需要对食管癌患者进行这些癌症的密切监测。